{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:56:45Z","timestamp":1793120205552,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH101498"],"award-info":[{"award-number":["MH101498"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41386-018-0136-3","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T05:12:16Z","timestamp":1530162736000},"page":"2154-2160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":225,"title":["The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects"],"prefix":"10.1038","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-6181","authenticated-orcid":false,"given":"Chadi G.","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M.","family":"De Feyter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette A.","family":"Averill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6142","authenticated-orcid":false,"given":"Christopher L.","family":"Averill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golam M. I.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerana","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin A.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Esterlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Juchem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme F.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"key":"136_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"136_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"136_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199\u2013214.","journal-title":"Arch Gen Psychiatry"},{"key":"136_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrd.2017.16","volume":"16","author":"JW Murrough","year":"2017","unstructured":"Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017;16:472\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"136_CR5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/schbul\/sbs069","volume":"38","author":"DC Javitt","year":"2012","unstructured":"Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP\/NMDA model of schizophrenia. Schizophr Bull. 2012;38:958\u201366.","journal-title":"Schizophr Bull"},{"key":"136_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/schbul\/sbs075","volume":"38","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Krystal JH. Capturing the angel in \u201cangel dust\u201d: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull. 2012;38:942\u20139.","journal-title":"Schizophr Bull"},{"key":"136_CR7","doi-asserted-by":"publisher","first-page":"1S","DOI":"10.1016\/S0006-3223(99)80008-0","volume":"45","author":"JH Krystal","year":"1999","unstructured":"Krystal JH, Berman RM, Skolnick P, Paul IA, Sanacora G. Glutamate and the pathophysiology and treatment of depression. Biol Psychiatry. 1999;45:1S\u201347S.","journal-title":"Biol Psychiatry"},{"key":"136_CR8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/nbm.1761","volume":"24","author":"RA de Graaf","year":"2011","unstructured":"de Graaf RA, Rothman DL, Behar KL. State of the art direct 13C and indirect 1H-[13C] NMR spectroscopy in vivo. A practical guide. NMR Biomed. 2011;24:958\u201372.","journal-title":"NMR Biomed"},{"key":"136_CR9","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1176\/appi.ajp.2014.14010067","volume":"171","author":"CG Abdallah","year":"2014","unstructured":"Abdallah CG, Jiang L, De Feyter HM, Fasula M, Krystal JH, Rothman DL, et al. Glutamate metabolism in major depressive disorder. Am J Psychiatry. 2014;171:1320\u20137.","journal-title":"Am J Psychiatry"},{"key":"136_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/nbm.1772","volume":"24","author":"DL Rothman","year":"2011","unstructured":"Rothman DL, De Feyter HM, de Graaf RA, Mason GF, Behar KL. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 2011;24:943\u201357.","journal-title":"NMR Biomed"},{"key":"136_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/nbm.1524","volume":"23","author":"S Li","year":"2010","unstructured":"Li S, Zhang Y, Wang S, Araneta MF, Johnson CS, Xiang Y, et al. 13C MRS of occipital and frontal lobes at 3\u2009T using a volume coil for stochastic proton decoupling. NMR Biomed. 2010;23:977\u201385.","journal-title":"NMR Biomed"},{"key":"136_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/mrm.22044","volume":"62","author":"S Li","year":"2009","unstructured":"Li S, Zhang Y, Wang S, Yang J, Ferraris Araneta M, Farris A, et al. In vivo 13C magnetic resonance spectroscopy of human brain on a clinical 3\u2009T scanner using [2-13C]glucose infusion and low-power stochastic decoupling. Magn Reson Med. 2009;62:565\u201373.","journal-title":"Magn Reson Med"},{"key":"136_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jmr.2008.09.012","volume":"195","author":"N Sailasuta","year":"2008","unstructured":"Sailasuta N, Robertson LW, Harris KC, Gropman AL, Allen PS, Ross BD. Clinical NOE 13C MRS for neuropsychiatric disorders of the frontal lobe. J Magn Reson. 2008;195:219\u201325.","journal-title":"J Magn Reson"},{"key":"136_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2470547017697317","volume":"1","author":"B Hare","year":"2017","unstructured":"Hare B, Ghosal S, Duman R. Rapid acting antidepressants in chronic stress models: molecular and cellular mechanisms. Chronic Stress. 2017;1:1\u201316.","journal-title":"Chronic Stress"},{"key":"136_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pharmthera.2018.05.010","volume":"190","author":"Chadi G. Abdallah","year":"2018","unstructured":"Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation? Pharmacol Ther. 2018. \n                    https:\/\/doi.org\/10.1016\/j.pharmthera.2018.05.010\n                    \n                  .","journal-title":"Pharmacology & Therapeutics"},{"key":"136_CR16","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.biopsych.2011.11.006","volume":"71","author":"GM Chowdhury","year":"2012","unstructured":"Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine\u2019s effect on amino acid neurotransmitter metabolism. Biol Psychiatry. 2012;71:1022\u20135.","journal-title":"Biol Psychiatry"},{"key":"136_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/mp.2016.34","volume":"22","author":"GM Chowdhury","year":"2017","unstructured":"Chowdhury GM, Zhang J, Thomas M, Banasr M, Ma X, Pittman B, et al. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry. 2017;22:120\u20136.","journal-title":"Mol Psychiatry"},{"key":"136_CR18","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1073\/pnas.1214912110","volume":"110","author":"F Hyder","year":"2013","unstructured":"Hyder F, Rothman DL, Bennett MR. Cortical energy demands of signaling and nonsignaling components in brain are conserved across mammalian species and activity levels. Proc Natl Acad Sci USA. 2013;110:3549\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"136_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.tins.2004.06.005","volume":"27","author":"RG Shulman","year":"2004","unstructured":"Shulman RG, Rothman DL, Behar KL, Hyder F. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci. 2004;27:489\u201395.","journal-title":"Trends Neurosci"},{"key":"136_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/archgenpsychiatry.2007.37","volume":"65","author":"JF Deakin","year":"2008","unstructured":"Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008;65:154\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"136_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","volume":"179","author":"JH Krystal","year":"2005","unstructured":"Krystal JH, Abi-Saab W, Perry E, D\u2019Souza DC, Liu N, Gueorguieva R, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl). 2005;179:303\u20139.","journal-title":"Psychopharmacology (Berl)"},{"key":"136_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/11533230-000000000-00000","volume":"24","author":"JH Krystal","year":"2010","unstructured":"Krystal JH, Mathew SJ, D\u2019Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs. 2010;24:669\u201393.","journal-title":"CNS Drugs"},{"key":"136_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","volume":"57","author":"A Anand","year":"2000","unstructured":"Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57:270\u20136.","journal-title":"Arch Gen Psychiatry"},{"key":"136_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jmr.2017.08.004","volume":"283","author":"H Chen","year":"2017","unstructured":"Chen H, De Feyter HM, Brown PB, Rothman DL, Cai S, de Graaf RA. Comparison of direct (13)C and indirect (1)H-[(13)C] MR detection methods for the study of dynamic metabolic turnover in the human brain. J Magn Reson. 2017;283:33\u201344.","journal-title":"J Magn Reson"},{"key":"136_CR25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/npp.2011.295","volume":"37","author":"DC D\u2019Souza","year":"2012","unstructured":"D\u2019Souza DC, Singh N, Elander J, Carbuto M, Pittman B, de Haes JU, et al. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology. 2012;37:1036\u201346.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"136_CR26","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.biopsych.2011.09.031","volume":"71","author":"Handan Gunduz-Bruce","year":"2012","unstructured":"Gunduz-Bruce H, Reinhart RM, Roach BJ, Gueorguieva R, Oliver S, D\u2019Souza DC, et al. Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry. 2012;71:969\u201377.","journal-title":"Biological Psychiatry"},{"key":"136_CR27","doi-asserted-by":"publisher","first-page":"E100","DOI":"10.1152\/ajpendo.2001.281.1.E100","volume":"281","author":"R Gruetter","year":"2001","unstructured":"Gruetter R, Seaquist ER, Ugurbil K. A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. Am J Physiol Endocrinol Metab. 2001;281:E100\u201312.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"136_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/npp.2011.181","volume":"37","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37:4\u20135.","journal-title":"Neuropsychopharmacology"},{"key":"136_CR29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1176\/ajp.154.6.805","volume":"154","author":"A Breier","year":"1997","unstructured":"Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry. 1997;154:805\u201311.","journal-title":"Am J Psychiatry"},{"key":"136_CR30","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/mp.2012.194","volume":"18","author":"NR Driesen","year":"2013","unstructured":"Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D\u2019Souza DC, et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry. 2013;18:1199\u2013204.","journal-title":"Mol Psychiatry"},{"key":"136_CR31","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1038\/npp.2013.170","volume":"38","author":"NR Driesen","year":"2013","unstructured":"Driesen NR, McCarthy G, Bhagwagar Z, Bloch MH, Calhoun VD, D\u2019Souza DC, et al. The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology. 2013;38:2613\u201322.","journal-title":"Neuropsychopharmacology"},{"key":"136_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamapsychiatry.2017.3572","volume":"75","author":"DC Javitt","year":"2018","unstructured":"Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. JAMA Psychiatry. 2018;75:11\u20139.","journal-title":"JAMA Psychiatry"},{"key":"136_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","volume":"7","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7:25\u201338.","journal-title":"Eur Neuropsychopharmacol"},{"key":"136_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0924-977X(96)00039-9","volume":"7","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol. 1997;7:9\u201324.","journal-title":"Eur Neuropsychopharmacol"},{"key":"136_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.biopsych.2014.07.022","volume":"77","author":"A Anticevic","year":"2015","unstructured":"Anticevic A, Corlett PR, Cole MW, Savic A, Gancsos M, Tang Y, et al. N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. Biol Psychiatry. 2015;77:569\u201380.","journal-title":"Biol Psychiatry"},{"key":"136_CR36","doi-asserted-by":"publisher","first-page":"16720","DOI":"10.1073\/pnas.1208494109","volume":"109","author":"A Anticevic","year":"2012","unstructured":"Anticevic A, Gancsos M, Murray JD, Repovs G, Driesen NR, Ennis DJ, et al. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci USA. 2012;109:16720\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"136_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.bpsc.2017.04.006","volume":"2","author":"CG Abdallah","year":"2017","unstructured":"Abdallah CG, Averill CL, Salas R, Averill LA, Baldwin PR, Krystal JH, et al. Prefrontal connectivity and glutamate transmission: relevance to depression pathophysiology and ketamine treatment. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2:566\u201374.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"136_CR38","doi-asserted-by":"publisher","first-page":"247054701771091","DOI":"10.1177\/2470547017710916","volume":"1","author":"Margaret T. Davis","year":"2017","unstructured":"Davis MT, Holmes SE, Pietrzak RH, Esterlis I. Neurobiology of chronic stress-related psychiatric disorders: evidence from molecular imaging studies. Chronic Stress. 2017;1. \n                    https:\/\/doi.org\/10.1177\/2470547017710916\n                    \n                  .","journal-title":"Chronic Stress"},{"key":"136_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.biopsych.2014.06.024","volume":"77","author":"C DeLorenzo","year":"2015","unstructured":"DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, et al. In vivo ketamine-induced changes in [(11)C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry. 2015;77:266\u201375.","journal-title":"Biol Psychiatry"},{"key":"136_CR40","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/mp.2017.58","volume":"23","author":"I Esterlis","year":"2018","unstructured":"Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [(11)C]ABP688 and PET imaging study in depression. Mol Psychiatry. 2018;23:824\u201332.","journal-title":"Mol Psychiatry"},{"key":"136_CR41","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mp.2015.83","volume":"21","author":"MS Milak","year":"2016","unstructured":"Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry. 2016;21:320\u20137.","journal-title":"Mol Psychiatry"},{"key":"136_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1176\/appi.ajp.162.2.394","volume":"162","author":"LM Rowland","year":"2005","unstructured":"Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005;162:394\u20136.","journal-title":"Am J Psychiatry"},{"key":"136_CR43","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/mp.2011.171","volume":"17","author":"JM Stone","year":"2012","unstructured":"Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reed LJ, et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. 2012;17:664\u20135.","journal-title":"Mol Psychiatry"},{"key":"136_CR44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0269881111405359","volume":"26","author":"MJ Taylor","year":"2012","unstructured":"Taylor MJ, Tiangga ER, Mhuircheartaigh RN, Cowen PJ. Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J Psychopharmacol. 2012;26:733\u20137.","journal-title":"J Psychopharmacol"},{"key":"136_CR45","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/sj.npp.1300252","volume":"28","author":"JH Krystal","year":"2003","unstructured":"Krystal JH, Petrakis IL, Limoncelli D, Webb E, Gueorgueva R, D\u2019Souza DC, et al. Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology. 2003;28:2020\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"136_CR46","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1176\/ajp.161.10.1776","volume":"161","author":"IL Petrakis","year":"2004","unstructured":"Petrakis IL, Limoncelli D, Gueorguieva R, Jatlow P, Boutros NN, Trevisan L, et al. Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry. 2004;161:1776\u201382.","journal-title":"Am J Psychiatry"},{"key":"136_CR47","doi-asserted-by":"crossref","unstructured":"De Feyter HM, Herzog RI, Steensma BR, Klomp DWJ, Brown PB, Mason GF, et al. Selective proton-observed, carbon-edited (selPOCE) MRS method for measurement of glutamate and glutamine (13) C-labeling in the human frontal cortex. Magn Reson Med. 2018;80:11\u201320.","DOI":"10.1002\/mrm.27003"},{"key":"136_CR48","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","volume":"17","author":"B Moghaddam","year":"1997","unstructured":"Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921\u20137.","journal-title":"J Neurosci"},{"key":"136_CR49","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/da.22501","volume":"33","author":"CG Abdallah","year":"2016","unstructured":"Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH. Ketamine\u2019s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety. 2016;33:689\u201397.","journal-title":"Depress Anxiety"},{"issue":"1","key":"136_CR50","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.biopsych.2017.10.020","volume":"84","author":"Thu Ha Pham","year":"2018","unstructured":"Pham TH, Defaix C, Xu X, Deng SX, Fabresse N, Alvarez JC, et al. Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects. Biol Psychiatry. 2018;84:e3\u20136.","journal-title":"Biological Psychiatry"},{"key":"136_CR51","first-page":"S111","volume":"43","author":"R Schwarcz","year":"2017","unstructured":"Schwarcz R, Wu H-Q, Zanos P, Gould T. Endogenous kynurenic acid mediates ketamine- and (2R,6R)-hydroxynorketamine-induced increases in extracellular glutamate and antidepressant actions. Neuropsychopharmacology. 2017;43:S111.","journal-title":"Neuropsychopharmacology"},{"key":"136_CR52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.biopsych.2013.04.025","volume":"74","author":"B Voleti","year":"2013","unstructured":"Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74:742\u20139.","journal-title":"Biol Psychiatry"},{"key":"136_CR53","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1172\/JCI85033","volume":"126","author":"ES Wohleb","year":"2016","unstructured":"Wohleb ES, Wu M, Gerhard DM, Taylor SR, Picciotto MR, Alreja M, et al. GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. J Clin Invest. 2016;126:2482\u201394.","journal-title":"J Clin Invest"},{"key":"136_CR54","first-page":"S111","volume":"43","author":"K Fukumoto","year":"2017","unstructured":"Fukumoto K, Kato T, Li X-Y, Duman R. Role of BDNF\/mTORC1 signaling in the long-lasting antidepressant effects of (2R,6R)-hydroxynorketamine. Neuropsychopharmacology. 2017;43:S111.","journal-title":"Neuropsychopharmacology"},{"key":"136_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.biopsych.2017.06.017","volume":"83","author":"S Ghosal","year":"2018","unstructured":"Ghosal S, Bang E, Yue W, Hare BD, Lepack AE, Girgenti MJ, et al. Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine. Biol Psychiatry. 2018;83:29\u201337.","journal-title":"Biol Psychiatry"},{"key":"136_CR56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.biopsych.2017.10.026","volume":"83","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD. Intracellular signaling pathways involved in (S)- and (R)-ketamine antidepressant actions. Biol Psychiatry. 2018;83:2\u20134.","journal-title":"Biol Psychiatry"},{"key":"136_CR57","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/npp.2016.186","volume":"42","author":"CG Abdallah","year":"2017","unstructured":"Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, et al. Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology. 2017;42:1210\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"136_CR58","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/hbm.23235","volume":"37","author":"JW Murrough","year":"2016","unstructured":"Murrough JW, Abdallah CG, Anticevic A, Collins KA, Geha P, Averill LA, et al. Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. Hum Brain Mapp. 2016;37:3214\u201323.","journal-title":"Hum Brain Mapp"},{"key":"136_CR59","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/npp.2017.229","volume":"43","author":"D Scheinost","year":"2018","unstructured":"Scheinost D, Holmes SE, DellaGioia N, Schleifer C, Matuskey D, Abdallah CG, et al. Multimodal investigation of network level effects using intrinsic functional connectivity, anatomical covariance, and structure-to-function correlations in unmedicated major depressive disorder. Neuropsychopharmacology. 2018;43:1119\u201327.","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0136-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:34Z","timestamp":1684616614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0136-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0136-3","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]},"assertion":[{"value":"17 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CGA has served as a consultant and\/or on advisory boards for Genentech and Janssen, and editor of \u201cChronic Stress\u201d for Sage Publications, Inc. JHK is a consultant for AbbVie, Inc., Amgen, Astellas Pharma Global Development, Inc., AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol\u2013Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Inc., Neurovance, Inc., FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Inc., Sage Therapeutics, Inc., Sunovion Pharmaceuticals, Inc., and Takeda Industries. JHK is on the Scientific Advisory Board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc., Naurex, Inc., and Pfizer. JHK is a stockholder in Biohaven Pharmaceuticals, holds stock options in Mnemosyne Pharmaceuticals, Inc., holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, U.S. Patent No. 5,447,948 (issued September 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, U.S. Patent No. 8,778,979 (issued July 15, 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression. U.S. Application No. 14\/197,767 (filed on March 5, 2014); U.S. application or Patent Cooperation Treaty international application No. 14\/306,382 (filed on June 17, 2014). GS reports personal consulting fees from Alkermes, Allergan, Biohaven Pharmaceuticals, Eli Lilly and Co., Genentech, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lundbeck Research USA, Merck & Co., Naurex, Navitor Pharmaceuticals, Noven Pharmaceuticals, Teva Pharmaceuticals Industries, Taisho Pharmaceutical Co., Takeda Pharmaceutical Co., Sage Pharmaceuticals, Inc., Sevier, Valeant Pharmaceuticals, and Vistagen Therapeutics, Inc. GS has grants and research contracts from Eli Lilly and Co., Janssen Pharmaceuticals, Merck & Co., and Sevier; and support from Sanofi-Aventis, in the form of free medication for an NIH sponsored study over the last 36 months. In addition, Dr. GS is a stockholder and holds stock options in Biohaven Pharmaceuticals; and has a patent for Glutamate Modulating Agents in the Treatment of Mental Disorders, U.S. Patent No. 8,778,979 (issued July 15, 2014) with royalties paid from Biohaven Pharmaceuticals. GFM is a consultant for Sumitomo Dainippon Pharma Co. Ltd. and UCB Pharma SA, and serves on the Scientific Advisory Board of Elucidata, Inc. All other authors report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All study procedures were approved by an institutional review board (ClinicalTrials.gov NCT02037035).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}